C. STOCKHOLDERS EQUITY (Tables)

6 Months Ended

Mar. 31, 2019

Equity [Abstract]

Changes in stockholders' equity

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total
BALANCES AT OCTOBER 1, 2018		28,034,487		$	280,346		$	331,312,184		$	(331,591,614	)	$	916
Warrant exercises		298,682			2,987			646,766			-			649,753
401(k) contributions paid in common stock		12,279			123			35,118			-			35,241
Stock issued to nonemployees for service		62,784			628			201,752			-			202,380
Shares returned for settlement of clinical research costs		(564,905	)		(5,649	)		5,649			-			-
Equity based compensation - employees		-			-			573,660			-			573,660
Net income		-			-			-			1,245,902			1,245,902
BALANCES AT DECEMBER 31, 2018		27,843,327			278,435			332,775,129			(330,345,712	)		2,707,852
Warrant exercises		1,523,933			15,239			2,640,395			-			2,655,634
401(k) contributions paid in common stock		10,419			104			36,779			-			36,883
Stock issued to nonemployees for service		77,449			774			224,855			-			225,629
Equity based compensation - employees		(3,500	)		(35	)		530,865			-			530,830
Shares issued for settlement of clinical research costs		500,000			5,000			1,285,000			-			1,290,000
Stock issuance costs		-			-			(43,625	)		-			(43,625	)
Net loss		-			-			-			(6,447,681	)		(6,447,681	)
BALANCES AT MARCH 31, 2019		29,951,628		$	299,517		$	337,449,398		$	(336,793,393	)	$	955,522

The changes in stockholders’ equity during the six months ended March 31, 2018 are as follows:

					Additional
	Common		Stock		Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total
BALANCES AT OCTOBER 1, 2017		11,903,133	$	119,031	$	296,298,401		$	(299,754,409	)	$	(3,336,977	)
Sale of common stock		1,289,478		12,895		2,437,105			-			2,450,000
401(k) contributions paid in common stock		18,984		190		35,690			-			35,880
Stock issued to nonemployees for service		13,705		137		25,270			-			25,407
Equity based compensation - employees		-		-		1,448,098			-			1,448,098
Net loss		-		-		-			(6,187,830	)		(6,187,830	)
BALANCES AT DECEMBER 31, 2017		13,258,051		132,581		300,975,618			(305,942,239	)		(4,834,040	)
Sale of common stock		2,501,145		25,011		4,652,130			-			4,667,141
401(k) contributions paid in common stock		25,901		259		36,261			-			36,520
Stock issued to nonemployees for service		124,082		1,241		227,254			-			228,495
Equity based compensation - employees		-		-		279,817			-			279,817
Conversion of notes payable and interest to common stock		55,373		554		108,746			-			109,300
Shares issued for settlement of clinical research costs		660,000		6,600		1,240,800			-			1,247,400
Stock issuance cost		-		-		(94,773	)		-			(94,773	)
Net loss		-		-		-			(4,708,135	)		(4,708,135	)
BALANCES AT MARCH 31, 2018		16,624,552	$	166,246	$	307,425,853		$	(310,650,374	)	$	(3,058,275	)

Stock options, stock bonuses and compensation granted by the Company

Stock options, stock bonuses and compensation granted by the Company as of March 31, 2019 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans
Incentive Stock Options Plans		138,400		123,558		N/A		385
Non-Qualified Stock Option Plans		3,387,200		3,010,476		N/A		335,619
Stock Bonus Plans		783,760		N/A		322,928		460,799
Stock Compensation Plan		134,000		N/A		115,590		18,410
Incentive Stock Bonus Plan		640,000		N/A		620,500		16,000

Stock options, stock bonuses and compensation granted by the Company as of September 30, 2018 are as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans
Incentive Stock Option Plans		138,400		123,558		N/A		385
Non-Qualified Stock Option Plans		3,387,200		3,036,569		N/A		309,526
Stock Bonus Plans		783,760		N/A		297,230		486,497
Stock Compensation Plan		134,000		N/A		118,590		15,410
Incentive Stock Bonus Plan		640,000		N/A		624,000		16,000

Stock option activity

	Six Months Ended March 31,
	2019	2018
Granted	500	10,300
Expired	2,400	24,379
Forfeited	24,193	1,393

	Three Months Ended March 31,
	2019	2018
Granted	-	-
Expired	-	584
Forfeited	24,193	6,856

Derivative liabilities, warrants and other options

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	2/18/2020
Series V	5/28/2015		810,127	$	19.75	5/28/2020
Series UU	6/11/2018		187,562	$	2.80	6/11/2020
Series W	10/28/2015		688,930	$	16.75	10/28/2020
Series X	1/13/2016		120,000	$	9.25	1/13/2021
Series Y	2/15/2016		26,000	$	12.00	2/15/2021
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021
Series BB	8/26/2016		16,000	$	13.75	8/22/2021
Series Z	5/23/2016		264,000	$	13.75	11/23/2021
Series FF	12/8/2016		68,048	$	3.91	12/1/2021
Series CC	12/8/2016		680,480	$	5.00	12/8/2021
Series HH	2/23/2017		20,000	$	3.13	2/16/2022
Series AA	8/26/2016		200,000	$	13.75	2/22/2022
Series JJ	3/14/2017		30,000	$	3.13	3/8/2022
Series LL	4/30/2017		26,398	$	3.59	4/30/2022
Series MM	6/22/2017		893,491	$	1.86	6/22/2022
Series NN	7/24/2017		539,300	$	2.52	7/24/2022
Series OO	7/31/2017		60,000	$	2.52	7/31/2022
Series QQ	8/22/2017		3,500	$	2.50	8/22/2022
Series GG	2/23/2017		200,000	$	3.00	8/23/2022
Series II	3/14/2017		216,500	$	3.00	9/14/2022
Series RR	10/30/2017		555,370	$	1.65	10/30/2022
Series KK	5/3/2017		213,870	$	3.04	11/3/2022
Series SS	12/19/2017		794,740	$	2.09	12/18/2022
Series TT	2/5/2018		1,210,827	$	2.24	2/5/2023
Series PP	8/28/2017		112,500	$	2.30	2/28/2023
Series WW	7/2/2018		69,225	$	1.63	6/28/2023
Series VV	7/2/2018		2,515,000	$	1.75	1/2/2024
Consultants	7/1/16 - 7/28/17		28,000	$	2.18-$11.50	6/30/2019- 7/27/2027

Tabular disclosure of derivative liabilities at fair value

	March 31, 2019		September 30, 2018
Series S warrants	$	-	$	33
Series V warrants		275,584		770,436
Series W warrants		383,053		999,081
Series Z warrants		372,936		487,767
Series ZZ warrants		21,577		34,215
Series AA warrants		287,206		380,474
Series BB warrants		20,720		28,456
Series CC warrants		1,440,026		1,779,724
Series DD warrants		-		1,249,287
Series EE warrants		-		1,249,287
Series FF warrants		154,318		188,921
Series GG warrants		500,478		607,228
Series HH warrants		48,174		58,816
Series II warrants		544,792		660,135
Series JJ warrants		72,716		88,642
Series KK warrants		543,463		656,930
Series LL warrants		62,886		77,632
Total warrant liabilities	$	4,727,929	$	9,317,064

Schedule of gains and (losses) on derivative liabilities

The table below presents the gains/(losses) on the warrant liabilities for the six months ended March 31:

	2019		2018
Series S warrants	$	33	$	11,927
Series V warrants		494,852		(3,547	)
Series W warrants		616,028		(24,131	)
Series Z warrants		114,831		8,095
Series ZZ warrants		12,638		189
Series AA warrants		93,268		8,676
Series BB warrants		7,736		293
Series CC warrants		339,698		41,919
Series DD warrants		1,249,287		5,456
Series EE warrants		1,249,287		5,456
Series FF warrants		34,603		7,301
Series GG warrants		106,750		37,419
Series HH warrants		10,642		2,683
Series II warrants		115,343		50,608
Series JJ warrants		15,926		4,010
Series KK warrants		113,467		36,924
Series LL warrants		14,746		3,307
Net gain on warrant liabilities	$	4,589,135	$	196,585

The table below presents the gains/(losses) on the warrant liabilities for the three months ended March 31:

	2019			2018
Series S warrants	$	-		$	(1,141	)
Series V warrants		(61,480	)		94,766
Series W warrants		(10,822	)		105,336
Series Z warrants		(89,290	)		63,630
Series ZZ warrants		(1,685	)		3,532
Series AA warrants		(63,951	)		56,036
Series BB warrants		(4,374	)		2,924
Series CC warrants		(325,908	)		238,740
Series DD warrants		-			(27	)
Series EE warrants		-			(27	)
Series FF warrants		(34,459	)		25,348
Series GG warrants		(106,032	)		152,551
Series HH warrants		(10,309	)		8,345
Series II warrants		(115,246	)		229,414
Series JJ warrants		(15,536	)		12,552
Series KK warrants		(114,628	)		151,951
Series LL warrants		(13,451	)		10,885
Net (loss)/gain on warrant liabilities	$	(967,171	)	$	1,154,815

Other non-operating gain (loss)

	Six Months Ended					Three Months Ended
	3/31/2019		3/31/2018			3/31/2019			3/31/2018
Amount realized through the resale of shares	$	1,711,353	$	1,225,291		$	559,177		$	478,590
Fair value of shares upon issuance		1,290,000		1,247,400			1,290,000			1,247,400
Other non-operating gain (loss)	$	421,353	$	(22,109	)	$	(730,823	)	$	(768,810	)